Investing.com - GlaxoSmithKline reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
GlaxoSmithKline announced earnings per share of £0.229 on revenue of £7.42B. Analysts polled by Investing.com anticipated EPS of £0.2154 on revenue of £7.85B.
GlaxoSmithKline shares are down 9% from the beginning of the year and are trading at £1,336.00 , down-from-52-week-high.They are under-performing the IBEX 35 which is up 8.85% from the start of the year.
GlaxoSmithKline shares lost 0.06% in intra-day trade the report.
GlaxoSmithKline follows other major Healthcare sector earnings this month
GlaxoSmithKline's report follows an earnings beat by Oxford BioMedica on Thursday, April 15, 2021, who reported EPS of £0.01 on revenue of £53.75M, compared to forecasts EPS of £-4.60 on revenue of £51.11M.
Silence Therapeutics had beat expectations on Monday, April 12, 2021 with first quarter EPS of £-0.26 on revenue of £4.33M, compared to forecast for EPS of £-20.70 on revenue of £2.40M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar